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Study 2010 confirms ischemic heart disease and stroke as
the leading cause of death and that hypertension is the
main associated risk factor worldwide. How best to
respond to the rising prevalence of hypertension in
resource-deprived settings is a topic of ongoing public-
health debate and discussion. In low-income and middle-
income countries, socioeconomic inequality and cultural
factors play a role both in the development of risk factors
and in the access to care. In Europe, cultural barriers and
poor communication between health systems and migrants
may limit migrants from receiving appropriate prevention,
diagnosis, and treatment. To use more efficiently resources
available and to make treatment cost-effective at the
patient level, cardiovascular risk approach is now
recommended. In 2011, The European Society of
Hypertension established a Working Group on
‘Hypertension and Cardiovascular risk in low resource
settings’, which brought together cardiologists,
diabetologists, nephrologists, clinical trialists,
epidemiologists, economists, and other stakeholders to
review current strategies for cardiovascular risk assessment
in population studies in low-income and middle-income
countries, their limitations, possible improvements, and
future interests in screening programs. This report
summarizes current evidence and presents highlights of
unmet needs.
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PERSPECTIVEA
ccording to the Global Burden of Disease (GBD)
2010 study, the most comprehensive and compar-
able assessment of mortality and loss of health to
date [1], cardiovascular disease (CVD) is the leading cause
of death worldwide, 80% of the 16.7 million deaths due to
CVD occur in low-income and middle-income countries
(LMICs) and hypertension is now the leading associatedorized reproduction of this article is prohibited.
DOI:10.1097/HJH.0000000000000125
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Modesti et al.risk factor [1,2]. High blood pressure (BP) accounts for
9.4 million (95% UI 8.6 million to 10.1 million) deaths
and 7.0% (6.2–7.7) of global disability-adjusted life years
(DALYs), more than elevated BMI, fasting plasma glucose,
and total cholesterol combined [2].
As of 2008, almost 1 billion people have uncontrolled
hypertension worldwide [3]. The African region has the
highest prevalence rate, 46% of adults aged 25 and above,
whereas the Americas have the lowest prevalence, at
35%. In contrast with other CVD risks such as high BMI,
the burden of hypertension is greater in lower income
countries than higher income settings [3,4]. In an urban
African setting, the stroke death rate (a proxy of hyper-
tension prevalence and control) was reported to be five-
fold higher than that in England [5,6]. According to WHO
data, age-standardized death rate (per 100 000 population)
is 141 in the African region and 93 in the European region
[7]. Multiple risk factors positively interact to exacerbate
CVD risks. Hypertension, for example, combined with
unhealthy diets and lack of physical activity (sodium and
alcohol consumption, high BMI, and low physical activity),
has a multiplicative negative effect on CVD mortality
and DALYs [2]. A substantial part of the CVD risk of death
and DALYs attributable to these factors is not also exacer-
bated by, but also mediated through high BP [2]. In LMICs,
overweight or obesity was associated with hypertension
[8–11] or progression to hypertension [12]. Cultural aspects
can also increase or decrease exposure to risk factors. The
odds of obesity in LMICs is especially high for women [13],
particularly in the Middle East and North Africa [14]. Sex
differences for abdominal obesity start at early adolescence
[15], probably due both to a preferred body image [16–18]
and to food insecurity [19–22]. Education and socio-
economic inequality seem to play a role in the development
of obesity [23] as well as in the access to care for hyper-
tension [10,24–30], especially in women. Sex association of
obesity in adulthood was indeed lost after accounting for
education and socioeconomic factors [20,31].
Hypertension is also a determinant of chronic kidney
disease (CKD), a recognized marker of the poor health
outcomes of hypertension and diabetes [32]. However,
growing evidence indicates that CKD is a strong cardio-
vascular risk factor in itself [32]. Other causes of CKD in
LMICs will be discussed later on in this article. In the general
population, glomerular filtration rates (GFRs) lower than
60ml/min/1.73m2 and albuminuria (one of the earliest
manifestations of CKD) were found to be associated with
an independent risk of cardiovascular morbidity and
mortality [33–36]. The fact that milder CKD affects 5–7%
of the world population and is more common in LMICs and
in disadvantaged and minority populations is worth noting
[37,38]. Taken together, these findings underline the add-on
role of CKD to the common recognized risk factors for
global and cardiovascular mortality.
How best to respond to the rising prevalence of
hypertension in resource-deprived settings is a topic of
ongoing public-health debate and discussion. On the
one hand, according to the Disease Control Priorities
Project, two prevention strategies at population level, salt
reduction and tobacco control, and a multidrug strategy
to treat patients with high-risk CVD meet the condition ofCopyright © Lippincott Williams & Wilkins. Unaut
2 www.jhypertension.comcost-effectiveness multiple interventions in LMICs [39,40].
Population strategies supported by communication media
with the concerted action of local authorities might induce
cultural changes and the adoption of healthy lifestyle.
On the other hand, WHO recommends identification of
individuals with high-risk CVD in LMICs to make cost-
effective the allocation of available resources. Cardiovas-
cular risk stratification might, however, require facilities not
easily available in LMICs. In 2011, the European Society of
Hypertension established a Working Group on ’Hyperten-
sion and Cardiovascular risk in low resource settings’,
which brought together cardiologists, diabetologists,
nephrologists, clinical trialists, and other stakeholders to
review current strategies for cardiovascular risk assessment
in population studies, their limitations, possible improve-
ments, and future interests in screening programs. This
report summarizes current evidence from the Working
Group and presents highlights of unmet needs for inter-
vention and research at patient and population levels.
PREVENTION STRATEGIES AT
POPULATION LEVEL
High sodium intake has effects on BP [41–43], all-cause
mortality, CVD, stroke, and coronary heart disease,
which have been recently quantified by the WHO Nutrition
Guidance Expert Advisory Group Subgroup on Diet and
Health [44–46]. When sodium intake was less than 2 g/day,
SBP was reduced by 3.47mmHg (0.76–6.18) and DBP
by 1.81mmHg (0.54– 3.08) as compared to a sodium intake
 2 g/day. Increased sodium intake was associated with an
increased risk of stroke (risk ratio 1.24, 95% confidence
interval 1.08–1.43), stroke mortality (1.63, 1.27–2.10), and
coronary heart disease mortality (1.32, 1.13–1.53) [47]. Esti-
mation of the effects of low-sodium vs. high-sodium intake
on BP showed a greater increase in hypertensive and black
populations than in normotensive individuals and whites,
respectively [48]. The 2002 joint World Health Organization/
Food and Agriculture Organization of the United Nations
expert consultation [49] and the 2007 WHO guideline [50]
recommend a sodium intake not greater than 2 g/day . In
LMICs, tobacco consumption is increasing by 3.4% per year
and smoking rates are also increasing [51,52]. In developed
countries, 35% of men and 22% of women smoke, whereas
in LMICs, 50% of men and 9% of women are smokers.
A favorable association between smoking cessation and
BP decrease over time and risk to develop hypertension
in an adult sample of generally healthy men has recently
been reported [53]. More than 50% of world’s population
now lives in urban areas where sodium consumption
and tobacco use are consistently high [28,54]. Mass
media campaigns have a direct impact on populations,
but are expensive and require the support of local
health authorities. An increasing proportion of governments
in western countries have moved to ban all promotion
of cigarettes and smoking via the electronic and print
media [55]. Involvement of mass media-newspapers,
magazines, radio, television, and films may change cultural
models and help in adopting healthy lifestyle by young
people. James Bond had his last cigarette in 1989 in ‘Licence
to kill’, but still drinks. Exposure to alcohol advertisinghorized reproduction of this article is prohibited.
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Cardiovascular risk assessment in low-resource settingsis strongly associated with the likelihood of adolescents
starting to drink [56,57], as well as with increased
alcohol consumption among young people [58,59]. Alcohol
consumption increases BP values both in hypertensive
andnormotensive individuals [60–62]. Attention should also
probably be paid on sugar in foods and beverages, an
independent risk factor in LMICs for the metabolic syn-
drome [63].
TREATMENT STRATEGYAT THE
PATIENT LEVEL
The multidrug strategy to treat patients with high cardio-
vascular risk also meets criteria for cost-effectiveness
[39,40,64,65], and WHO fully recognizes the paradigm shift
from the treatment of the single risk factor in isolation to the
management of total cardiovascular risk [50,66]. Identifi-
cation of patients with high-risk CVD is, thus, essential.
Cardiovascular risk stratification in low-income
and middle-income countries
The first limiting factor is that facilities required to assess
biochemical parameters for cardiovascular risk stratification
may not be easily available in LMICs. Therefore, cardio-
vascular risk stratification packages proposed in 2002 by
WHOwere based on history, BPmeasurement, and selective
urine analysis (performed only if BP 140 or 90mmHg)
[67]. More precisely, theWHO CVD-Risk Management Pack-
age considered three different scenarios (nonphysician
health worker; medical doctor or specially trained nurse;
medical doctorwith access to full specialist care; Table1) [68].
The second limitation is that most of available equations
developed to predict individual absolute risk of a cardio-
vascular event over a specified time period [69–76] were
derived from European descent populations in high-income
countries and are not necessarily valid in other populations
[75,77]. Therefore, WHO/International Society of Hyperten-
sion (ISH) produced specific risk prediction charts [50] using
population-based standardized collection and assessment of
data on risk factor prevalence and relative risk (heart attacks
and stroke). Data were obtained in WHO epidemiologic
subregion survey from the Comparative Risk Assessment
Project [54], and in the Asia Pacific Cohort Studies Collabor-
ation [78–82]. These charts have the samegoal as existing risk
equations such as those based on Framingham and SCORE
[69,72]. Absolute risk of cardiovascular events was deter-
mined by scaling individual relative risk to population
incidence rates of major CVDs, estimated from the GBD
study [50,65,66]. WHO/ISH charts enable cardiovascular risk
assessment and prediction in LMIC populations of all WHOCopyright © Lippincott Williams & Wilkins. Unauth
TABLE 1. Characteristics of the three scenarios in the WHO CVD-Risk
Resource availability Scenario 1 Scenario 2
Human resources Nonphysician health worker Medical doctor or
Equipment Stethoscope, blood pressure
measurement device, measuring
tape or weighing scale; Optional:
test tubes, holder, burner,
solution or test strips for
checking urine glucose
Stethoscope, bloo
device, measur
Test tubes, hold
test strips for c
and albumin
Data from [68].
Journal of Hypertensionsubregions on the basis of age, sex, SBP, type 2 diabetes
mellitus, smoking status, and total serum cholesterol [50,66].
Detection of abnormalities of glucose metabolism such as
impaired glucose tolerance, or the ’metabolic syndrome’ is
worthwhile, because some diabetes could be prevented by
focused intervention on lifestyle. Screening for diabetes is
more cost-effective for people in the hypertensive and obese
subgroups, the costs of screening being offset in many
groups by lower future treatment costs [83]. A third potential
limitation is that easy obesity measurements (BMI or waist
circumferences) are not included in the WHO/ISH charts,
although there is strong evidence of the importance of
obesity to guide intervention strategies aimed at reducing
the incidence of type 2 diabetes. The global rise in over-
weight and obesity suggests that health promotion inter-
ventions at population level have not so far been effective,
but improving lifestyles and increasing exercise in high-risk
individuals remains a crucial issue. Therefore to include
waist circumferences in the risk assessment could enhance
awareness. Assessment of proteinuria is also not included in
WHO charts, although recognizing that CVD risk may be
higher than indicated in the chart in people with proteinuria.
Implementation of cardiovascular risk strategies and
WHO/ISH Risk prediction charts in LMICs has different
implications. First, this approach restricts unnecessary drug
treatment to low-risk patients [84]. This point is especially
important in LMICs where much of the costs of healthcare
are currently shifted directly to patients. The WHO esti-
mates that out of pocket expenditure of more than 15–20%
can lead to impoverishment; India’s proportion in 2010 was
61% [85]. Achievement of universal health coverage is a
crucial step for sustainable development and for reducing
poverty and social inequality, and currently represents a
global goal of ‘Health for all as a human right’ [86]. Imple-
mentation of cardiovascular risk strategies in this context
might, thus, provide a way to use limited resources more
efficiently [87]. Second, the threshold of cardiovascular risk
for deciding the start of drug treatment can be adjusted to
suit the country context. Cost-effectiveness of an interven-
tion indeed depends on the gross domestic product per
head for the country. WHO proposed different 10-year total
CVD risk thresholds for intensive intervention based on
countries resource level (20% for high-resource setting; 30%
for medium-resource setting; 40% for low-resource setting).
Third, a little conflict with the main content may, however,
exist because although cardiovascular risk stratification
might be especially important for health systems of
countries with very limited resources, the screening or
identification of those with very high risk from the popu-
lation may be much more expensive than treating onlyorized reproduction of this article is prohibited.
Management Package
Scenario 3
specially trained nurse Medical doctor with access to full specialist care
d pressure measurement
ing tape or weighing scale;
er, burner, solution or
hecking urine glucose
Stethoscope, blood pressure measurement device,
measuring tape or weighing scale,
electrocardiograph, ophthalmoscope, urine
analysis, blood analysis: fasting blood sugar,
electrolytes, creatinine, cholesterol and
lipoproteins
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Modesti et al.hypertension. In many LMICs, facilities available for
cholesterol assay are limited, although it is often feasible
to check urine sugar as a surrogate measure for diabetes.
In this regard, WHO/ISH charts have a second version, for
use where measurement of cholesterol level is not possible
[50]. If the resources are really limited, it is a preferred
strategy to work only on hypertension and smoking and not
on lipid and diabetes because a lower risk is attributed
to them.
Despite drugs being a major contributor to healthcare
costs, Mendis et al. [84] found that reducing the cardio-
vascular risk threshold for drug treatment from 30 to 20% in
LMIC populations did not substantially increase the cost of
treatment. Moreover, as the cardiovascular risk threshold
for drug treatment is lowered, there is a concomitant
increase in health benefits [67].
Cardiovascular risk assessment in population
surveys
When performing population surveys in LMICs, a door-to-
door approach has different advantages: data collectedwith
a door-to-door approach allow avoiding the selection
bias affecting hospital data in LMICs where universal
health coverage is uncommon; the use of point-of-care
instruments for biochemical assays of blood glucose
and lipids, the procedure suggested by WHO, limits pre-
analytical errors (storage, transportation, standardization of
procedure) [88]. WHO recommends the use of affordable
and reliable electronic devices for BP measurement that
have the option to select manual readings [89–91]. Cost of
personnel is a main component of budget in population
surveys. Personnel costs and the logistic difficulties
connected with organizing a two-visit strategy, therefore,
lead to the adoption of a single-visit strategy in the WHO
STEPwise Approach to Stroke Surveillance [92] (STEPS)
aimed at assessing cardiovascular risk in populations.
Although the program allows structured between countries
comparison and within country follow-up of implementa-
tion of prevention strategies, its results cannot be directly
transferred to cost estimation for the plan of prevention
strategies. High BP is the main factor guiding cardiovascular
risk stratification and the diagnosis of hypertension requires
recording BP values for several days in repeated visits
[93–95]. When the estimation of hypertension prevalence
based on two visits was compared with the estimationCopyright © Lippincott Williams & Wilkins. Unaut
1
Hypertensive at both visits
Hypertensive at Visit 2
Hypertensive at Visit 1
1307 / 8889
1949 / 8247
1624 / 8572
Hyp / No Hyp
RR (95% 
FIGURE 1 Diagnosis of hypertension (SBP 140mmHg and/or diastolic blood pressure
interview) performed on the basis of measurements taken at the first visit (visit 1), at the
condition and age-weighted rates are reported [98]. CI, confidence interval.
4 www.jhypertension.combased on a single visit, the strategy adopted in the STEP
program, hypertension prevalence reduced by 12% in
a cohort of individuals aged 62 11 years [96], by 35% in
a cohort of individuals aged 39 9 years [97], and by 35%
in a national wide survey for the age range between 15 and
69 years (Fig. 1) [98]. Differently from what was expected,
misclassification is more common at young ages, two-thirds
of men less than 30 years of age having normal BP values at
the second visit [98]. Thus, screening an individual at high
cardiovascular risk at the first visit is crucial, but the panel of
tests that can be included in surveys is to be seen in the
perspective of costs. It is indeed unreliable to perform an
echocardiogram in all participants in a national survey.
However, the inclusion of a urine dipstick test for protein-
uria in the test panel might be a sustainable approach.
Proteinuria allows classifying a patient in the high or very
high class of 10-year risk of cardiovascular mortality as
defined by international guidelines for the management
of hypertension [93–95,99,100]. When urine dipstick for
proteinuria was added to the parameters included in a
national survey based on two-visit assessments [98], the
prevalence of individuals classified as at high or very high
cardiovascular risk at the first visit remained stable at the
second visit. More precisely, only 1.9% of individuals
classified as at high or very high cardiovascular risk at
the first visit moved to average, low or moderate cardio-
vascular risk categories at the second visit [98]. With this
approach, a stable estimation of individuals at high cardio-
vascular risk could be obtained already at the first visit.Implications for chronic kidney disease
assessment in low-income and middle-income
countries
In western countries, the current debated question is ‘who
should be screened to make cost-effective urine dipstick for
proteinuria?’. Diabetes and hypertension are the leading
causes of CKD in all developed and in many developing
countries [32], so that current trend is to perform a ‘selective
screening’ [101,102]. WHO suggests performing urine dip-
stick test only if clinic BP is at least 140 or at least 90mmHg,
and dipstick test for proteinuria is not included in the WHO
STEP program. However, risk factors may differ in other
areas of the world [103,104] because glomerulonephritis
and renal diseases of unknown causes are common in Asiahorized reproduction of this article is prohibited.
1.3 1.6 2
RR (95% Cl)
1 (reference)
1.66 (1.55 to 1.80)
1.36 (1.26 to 1.48)
Rate (95% Cl)
12.8 (12.2 to 13.4)
10.5 (9.9 to 11.0)
7.7 (7.2 to 8.1)
Cl)
90mm Hg and/or self-reported use of antihypertensive drugs at the time of the
second visit (visit 2), or both. The number of individuals with and without the
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Cardiovascular risk assessment in low-resource settingsand sub-Saharan African countries [105]. In China, where
the prevalence of proteinuria is high [106], glomerulo-
nephritis, mainly postinfectious, is the main cause
of CKD [105] and end-stage kidney disease [107–109].
Nephrotoxic effects can also result from consumption of
potentially toxic herbs, incorrect substitution of harmless
herbs with toxic herbs, contamination with toxic com-
pounds, such as heavy metals, or interactions between
herbs and conventional treatments [105,107,110,111]. The
use of khat in Yemen was importantly associated with
kidney damage (proteinuria  þ1) after adjustment for
several possible confounders (including hypertension
and diabetes) [112]. Data collected from Nepal, Bolivia
[113], and Yemen [10,112] showed that more than 5% of
people younger than 60 years without previous history
of diabetes and hypertension had microalbuminuria or
proteinuria (Fig. 2, Table 2) [112,113]. On these bases,
the Asian Forum of Chronic Kidney Disease Initiative
recently suggested the addition of region-specific high-risk
groups for screening, such as people exposed to harmful
herbal preparations [111] or environmental factors [114].
In the absence of prospective studies performed in LMICs, it
is impossible to infer that proteinuria, on a completely
different background, should carry the same risk found
in studies performed in industrialized societies. Likewise,
although evidence for the benefits of CKD treatment with
angiotensin-converting enzyme inhibitors and angiotensin
II receptor blockers in patients with albuminuria combined
with diabetes or CVD is strong in high-income countries
[115], no randomized clinical trials have been performed in
LMICs. However, integration of the urine dipstick test
in screening surveys opens a perspective for sustainable
cardiovascular risk assessment, and may increase health
awareness in countries without advanced health systems
[116]. The approach could be adapted to the conditions
and socioeconomic circumstances of each nation [110].
The existing Manichean dualism of communicable
and noncommunicable disease might lead physicians
and researchers to disregard the evidence that some com-
municable diseases of children are the cause of cardio-
vascular events in adulthood. Rheumatic heart diseaseCopyright © Lippincott Williams & Wilkins. Unauth
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HHypertension
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Proteinuria
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FIGURE 2 Venn diagram showing the amount of overlap between hypertension, diabe
rural area (n¼4775). Data are expressed as percentage of urban or rural individuals, the
Journal of Hypertension(RHD) is still causing most of the cardiovascular morbidity
and mortality in young people in different world areas
[117,118]. In China, RHD is a not negligible cause of atrial
fibrillation and stroke [119–121]. If RHD is detected
early, monthly penicillin injections (secondary prevention)
are a cost-effective means of preventing more advanced,
debilitating cardiac disease [122]. Costs make stethoscope
an essential equipment in cardiovascular risk stratification
(Table 1), although screening programs including primary
echocardiography revealed prevalence rates up to 10 times
higher than those resulting from clinical examination alone
[123–126]. In February 2012, the World Heart Federation
published the first evidence-based criteria for echocardio-
graphic diagnosis of RHD, and removed clinical examin-
ation from the diagnosis [127]. Ultraportable, hand-held,
pocket-sized imaging devices capable of producing two-
dimensional and color images are now available [128], but
in LMICs, physicians and expert sonographers are scarce.
The possibility that low-cost electronic stethoscope able
to reach a provisional diagnosis of cardiac valve disease
might be developed to screen heart murmurs in children
[129] is a sector of high potential interest [130]. These
devices might be accessible to unskilled personnel for
screening purposes.NEW VULNERABLE/HIGH-RISKGROUPS
IN EUROPEAN UNIONCOUNTRIES:
IMPLICATIONS FOR HEALTH SYSTEMS
In 2010, 9.4% of the total European Union populations
were foreign-born [131]. Age-standardized and sex-specific
stroke mortality rates in Great Britain for 1979–1983, 1989–
1993, and 1999–2003 were higher for all migrant groups
in each time period compared with men born in England
and Wales, men born in West Africa or Bangladesh,
and women from Jamaica having the highest rates.
More precisely in 1999–2003, stroke mortality was almost
200% higher among male migrants from West Africa,
and almost 100% higher among those from the Caribbean
[132]. These findings bear similarities with the high strokeorized reproduction of this article is prohibited.
(n = 4775)
1.3
(62)
5.6
(269)
0.3
(15)
0.2
(11)
1.7
(79)
2.3
Diabetes
ypertension
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RURAL
(111)
10.1
(482)
tes, and proteinuria separately for the individuals from the urban (n¼4390) and
absolute number being reported in brackets [112].
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TABLE 2. Prevalence of microalbuminuria proteinuria (1þ at dipstick test) in participants by country
Country
ACR (ACR>30mg/g) Proteinuria (1þ at dipstick test)
ReferenceAll Women Men All Women Men
Nepal 7.8 7.1 8.8 3.5 3.3 3.8 [113]
Bolivia – – – 4.5 4.0 5.5 [113]
Georgia – – – 14.0 11.6 21.5 [113]
Yemen – – – 6.2 5.3 7.0 [112]
USA 10.2 11.3 9.0 – – – [113]
ACR, albuminuria to creatininuria ratio.
Modesti et al.mortality of Surinamese and Antillean-born residents
in the Netherlands [133]. There is consensus that
among people of African origin, hypertension is three-fold
to four-fold more prevalent than the native European
population [75,134–139]. With few exceptions, incidence
and prevalence of diabetes mellitus are also much
higher among migrants than among locally born residents
[11,137,140,141]. In the UK, the incidence of end-stage
renal failure among individuals from ethnic communities
is three to five times greater than among the native
population [142,143]. Should these data be confirmed
in the different European countries, a future burden
of cardiovascular (myocardial infarction and stroke)
and renal disease (dialysis) can be expected in the
next few decades with relevant implications in terms
of costs for health systems of European Union member
countries.
European Union recognized the need to improve data
collection on migrants’ health aimed at the creation
of specific prevention policies. However, many of the
European Union programs have relied on the self-report
of pathological conditions. This approach was useful to
limit the costs of surveys, but sound data can only be
obtained by directly assessing risk factors with the adoption
of standardized forms to make results comparable between
countries.
Migrants from LMICs usually develop cardiovascular
complications in the medium-to-long term as a con-
sequence of different environmental circumstances
[77,144–147]. Cultural adaptations have great influence
on the effectiveness of interventions among specific popu-
lations [148–150]. Therefore, intervention should not be
focused only on the individual, but rather on the context
and community; otherwise change may not be sustainable
[151].
Policy initiatives should, thus, improve data collection,
to adapt organization of health systems to cultures, and to
provide information to migrants on health problems and
services. Europe as a whole is often perceived as a group of
wealthy countries where inclusive social protection systems
provide comprehensive protection for the most vulnerable
[154–156]. However, in times of financial constraint,
policy discussions often circle around cutting back social
protection expenditures. Only four European Union
member states (Netherlands, France, Portugal, and Spain)
offered undocumented migrants access to primary care
[131,152,153], but recent reductions in health expenditures
pose severe threats and lead to decisions limiting healthcare
to migrants without sufficiently investigating the impacts onCopyright © Lippincott Williams & Wilkins. Unaut
6 www.jhypertension.comthose in need [153]. A reduction in access to primary and
specialist care is indeed unlikely to be cost-effective, as
use of emergency services will increase [157,158]. Current
budget restrictions may also widen health inequalities,
hurting other population groups in the dominant ethnic
groups (lower socioeconomic groups, the unemployed
who comprise a very large group in Europe at present,
those with limited education, and people with mental
health issues) [159]. The drive to cost-effectiveness
should, thus, be coupled with seeing health as an invest-
ment, avoiding myopic short-term savings through arbitrary
healthcare cuts.
CONCLUSION
The clinical and epidemiological importance of CVD
and high BP in LMICs markedly increased during the last
decades and high BP is the leading risk factor. The estab-
lishment of culture of prevention in most LMICs requires
the concerted action of television, radio, mass media-
newspapers, and magazines, with the support of local
health ministries and regulatory agencies, to limit salt intake
and tobacco use.
Cost-effectiveness of prevention treatments at the
patient level requires a cardiovascular risk approach.
Identification of patients with high-risk CVD may indeed
restrict unnecessary drug treatment to low-risk patients.
The adoption of a cardiovascular risk approach in popu-
lation surveys has also relevant implications for healthcare
resource allocation decision-making. However, in low-
resource settings, the screening or identification of those
with very high risk from the population may be much
more expensive than treating only hypertension. Accord-
ing to current evidence, some crucial points have to be
considered both in surveys and patient care:ho1.rizHospital-based surveys have relevant selection
bias, universal health coverage being uncommon
in LMICs, so that a door-to-door approach is to be
preferred;2. Assessment of hypertension burden on the basis of a
single visit may lead to overestimation of prevalence
and healthcare requirements; thus survey strategies
aimed at assessing global cardiovascular risk have to
be considered;3. Treatment gap is to be based on cardiovascular risk
stratification (untreated individuals at high cardio-
vascular risk), rather than focusing on the single risk
factors (untreated hypertensive patients);ed reproduction of this article is prohibited.
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rnIntegration of urine dipstick test with cardiovascular
health programs enhances the value of screening
strategies;5. Proteinuria and CKD in LMICs may result from post-
infectious glomerulonephritis, or nephrotoxic agents
so that the value of selective screening (diabetes and
hypertension), currently adopted in high-income
countries, might be limited in LMICs;6. RHD still causes most of the cardiovascular morbidity
and mortality in LMICs, so that the development of
new strategies for optimization of the use of currently
available devices (ultrasound), or the development
of new low-cost device accessible to unskilled
personnel to screen heart murmurs in children is a
sector of high potential interest;7. Global changes may have relevant implications for
health systems of European countries, surveys
exploring cardiovascular risk being now essential
to focus prevention strategies in the setting of
migrants and underserved communities living in
Europe;8. Intervention in the setting of migrants should not
be focused only on the individual but rather on the
context and community; otherwise change may not
be sustainable.ACKNOWLEDGEMENTS
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